Pacritinib Versus Best Available Therapy to Treat Myelofibrosis
Status:
Terminated
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Phase 3, randomized, controlled study to evaluate the safety and efficacy of oral pacritinib
compared to Best Available Therapy (BAT) in patients with primary or secondary myelofibrosis.